6bj2 › Citations

Isolation of a Structural Mechanism for Uncoupling T Cell Receptor Signaling from Peptide-MHC Binding.

Sibener LV, Fernandes RA, Kolawole EM, Carbone CB, Liu F, McAffee D, Birnbaum ME, Yang X, Su LF, Yu W, Dong S, Gee MH, Jude KM, Davis MM, Groves JT, Goddard WA, Heath JR, Evavold BD, Vale RD, Garcia KC
Cell 174 672-687.e27 (2018)
Related entries: 6bj3, 6bj8

Cited: 158 times
EuropePMC logo PMID: 30053426

Abstract

TCR-signaling strength generally correlates with peptide-MHC binding affinity; however, exceptions exist. We find high-affinity, yet non-stimulatory, interactions occur with high frequency in the human T cell repertoire. Here, we studied human TCRs that are refractory to activation by pMHC ligands despite robust binding. Analysis of 3D affinity, 2D dwell time, and crystal structures of stimulatory versus non-stimulatory TCR-pMHC interactions failed to account for their different signaling outcomes. Using yeast pMHC display, we identified peptide agonists of a formerly non-responsive TCR. Single-molecule force measurements demonstrated the emergence of catch bonds in the activating TCR-pMHC interactions, correlating with exclusion of CD45 from the TCR-APC contact site. Molecular dynamics simulations of TCR-pMHC disengagement distinguished agonist from non-agonist ligands based on the acquisition of catch bonds within the TCR-pMHC interface. The isolation of catch bonds as a parameter mediating the coupling of TCR binding and signaling has important implications for TCR and antigen engineering for immunotherapy.

Reviews - 6bj2 mentioned but not cited (1)

  1. TCR Recognition of Peptide-MHC-I: Rule Makers and Breakers. Szeto C, Lobos CA, Nguyen AT, Gras S. Int J Mol Sci 22 E68 (2020)

Articles - 6bj2 mentioned but not cited (1)



Reviews citing this publication (61)

  1. The structural basis of T-cell receptor (TCR) activation: An enduring enigma. Mariuzza RA, Agnihotri P, Orban J. J Biol Chem 295 914-925 (2020)
  2. Chimeric antigen receptor signaling: Functional consequences and design implications. Lindner SE, Johnson SM, Brown CE, Wang LD. Sci Adv 6 eaaz3223 (2020)
  3. Computational Prediction and Validation of Tumor-Associated Neoantigens. Roudko V, Greenbaum B, Bhardwaj N. Front Immunol 11 27 (2020)
  4. Antigen processing and presentation in cancer immunotherapy. Lee MY, Jeon JW, Sievers C, Allen CT. J Immunother Cancer 8 e001111 (2020)
  5. Regulation of T Helper Cell Fate by TCR Signal Strength. Bhattacharyya ND, Feng CG. Front Immunol 11 624 (2020)
  6. Cell-cell interfaces as specialized compartments directing cell function. Belardi B, Son S, Felce JH, Dustin ML, Fletcher DA. Nat Rev Mol Cell Biol 21 750-764 (2020)
  7. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Lejeune M, Köse MC, Duray E, Einsele H, Beguin Y, Caers J. Front Immunol 11 762 (2020)
  8. Role of Mechanotransduction and Tension in T Cell Function. Rossy J, Laufer JM, Legler DF. Front Immunol 9 2638 (2018)
  9. Unraveling the mechanobiology of immune cells. Zhang X, Kim TH, Thauland TJ, Li H, Majedi FS, Ly C, Gu Z, Butte MJ, Rowat AC, Li S. Curr Opin Biotechnol 66 236-245 (2020)
  10. Membrane Ultrastructure and T Cell Activation. Pettmann J, Santos AM, Dushek O, Davis SJ. Front Immunol 9 2152 (2018)
  11. Predicting Cross-Reactivity and Antigen Specificity of T Cell Receptors. Lee CH, Salio M, Napolitani G, Ogg G, Simmons A, Koohy H. Front Immunol 11 565096 (2020)
  12. The CAR T-Cell Mechanoimmunology at a Glance. Li R, Ma C, Cai H, Chen W. Adv Sci (Weinh) 7 2002628 (2020)
  13. Dual Role of CD4 in Peripheral T Lymphocytes. Glatzová D, Cebecauer M. Front Immunol 10 618 (2019)
  14. Gaussian accelerated molecular dynamics for elucidation of drug pathways. Bhattarai A, Miao Y. Expert Opin Drug Discov 13 1055-1065 (2018)
  15. Molecular evolution of peptides by yeast surface display technology. Linciano S, Pluda S, Bacchin A, Angelini A. Medchemcomm 10 1569-1580 (2019)
  16. T-cell receptor affinity in the age of cancer immunotherapy. Hoffmann MM, Slansky JE. Mol Carcinog 59 862-870 (2020)
  17. Understanding the mechanistic basis of non-coding RNA through molecular dynamics simulations. Palermo G, Casalino L, Magistrato A, Andrew McCammon J. J Struct Biol 206 267-279 (2019)
  18. Dynamic bonds and their roles in mechanosensing. Zhu C, Chen Y, Ju LA. Curr Opin Chem Biol 53 88-97 (2019)
  19. Structural understanding of T cell receptor triggering. Xu X, Li H, Xu C. Cell Mol Immunol 17 193-202 (2020)
  20. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Klebanoff CA, Chandran SS, Baker BM, Quezada SA, Ribas A. Nat Rev Drug Discov 22 996-1017 (2023)
  21. Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. Isser A, Livingston NK, Schneck JP. Biomaterials 268 120584 (2021)
  22. Integrating Experiment and Theory to Understand TCR-pMHC Dynamics. Buckle AM, Borg NA. Front Immunol 9 2898 (2018)
  23. Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved. Fritsch EF, Burkhardt UE, Hacohen N, Wu CJ. Cancer Immunol Res 8 1465-1469 (2020)
  24. Mechanotransduction as a major driver of cell behaviour: mechanisms, and relevance to cell organization and future research. Puech PH, Bongrand P. Open Biol 11 210256 (2021)
  25. Adapting T Cell Receptor Ligand Discrimination Capability via LAT. Lo WL, Weiss A. Front Immunol 12 673196 (2021)
  26. Adaptive T cell immunotherapy in cancer. Ti D, Bai M, Li X, Wei J, Chen D, Wu Z, Wang Y, Han W. Sci China Life Sci 64 363-371 (2021)
  27. Mechanotransduction in T Cell Development, Differentiation and Function. Rushdi M, Li K, Yuan Z, Travaglino S, Grakoui A, Zhu C. Cells 9 E364 (2020)
  28. Thy-1, a Pathfinder Protein for the Post-genomic Era. Morris RJ. Front Cell Dev Biol 6 173 (2018)
  29. Tensile and compressive force regulation on cell mechanosensing. Chen Y, Li Z, Ju LA. Biophys Rev 11 311-318 (2019)
  30. Binding Analysis Using Accelerated Molecular Dynamics Simulations and Future Perspectives. Pawnikar S, Bhattarai A, Wang J, Miao Y. Adv Appl Bioinform Chem 15 1-19 (2022)
  31. Immune Literacy: Reading, Writing, and Editing Adaptive Immunity. Csepregi L, Ehling RA, Wagner B, Reddy ST. iScience 23 101519 (2020)
  32. DNA Nanotechnology for Investigating Mechanical Signaling in the Immune System. Hu Y, Duan Y, Salaita K. Angew Chem Int Ed Engl 62 e202302967 (2023)
  33. Enhanced sampling without borders: on global biasing functions and how to reweight them. Kamenik AS, Linker SM, Riniker S. Phys Chem Chem Phys 24 1225-1236 (2022)
  34. Mechanism of RNA recognition by a Musashi RNA-binding protein. Wang J, Lan L, Wu X, Xu L, Miao Y. Curr Res Struct Biol 4 10-20 (2022)
  35. Membrane Organization and Physical Regulation of Lymphocyte Antigen Receptors: A Biophysicist's Perspective. Limozin L, Puech PH. J Membr Biol 252 397-412 (2019)
  36. Biomechanics of T Cell Dysfunctions in Chronic Diseases. Gunasinghe SD, Peres NG, Goyette J, Gaus K. Front Immunol 12 600829 (2021)
  37. Mechanistic diversity in MHC class I antigen recognition. Barbosa CRR, Barton J, Shepherd AJ, Mishto M. Biochem J 478 4187-4202 (2021)
  38. Mechanosurveillance: Tiptoeing T Cells. Göhring J, Schrangl L, Schütz GJ, Huppa JB. Front Immunol 13 886328 (2022)
  39. Neuromechanobiology: An Expanding Field Driven by the Force of Greater Focus. Motz CT, Kabat V, Saxena T, Bellamkonda RV, Zhu C. Adv Healthc Mater 10 e2100102 (2021)
  40. What's the Catch? The Significance of Catch Bonds in T Cell Activation. Faust MA, Rasé VJ, Lamb TJ, Evavold BD. J Immunol 211 333-342 (2023)
  41. Staggered starts in the race to T cell activation. Richard AC, Frazer GL, Ma CY, Griffiths GM. Trends Immunol 42 994-1008 (2021)
  42. TCR mimic compounds for pHLA targeting with high potency modalities in oncology. Gerber HP, Presta LG. Front Oncol 12 1027548 (2022)
  43. Regulations of T Cell Activation by Membrane and Cytoskeleton. Kaizuka Y. Membranes (Basel) 10 E443 (2020)
  44. Relationship of 2D Affinity to T Cell Functional Outcomes. Kolawole EM, Lamb TJ, Evavold BD. Int J Mol Sci 21 E7969 (2020)
  45. Supported Lipid Bilayers and the Study of Two-Dimensional Binding Kinetics. Dam T, Chouliara M, Junghans V, Jönsson P. Front Mol Biosci 9 833123 (2022)
  46. The Energetic Landscape of Catch Bonds in TCR Interfaces. Ayres CM, Corcelli SA, Baker BM. J Immunol 211 325-332 (2023)
  47. The physical landscape of CAR-T synapse. Xiong Y, Libby KA, Su X. Biophys J 123 2199-2210 (2024)
  48. Immune-mediated alopecias and their mechanobiological aspects. Watson VE, Faniel ML, Kamili NA, Krueger LD, Zhu C. Cells Dev 170 203793 (2022)
  49. Is There a Need for a More Precise Description of Biomolecule Interactions to Understand Cell Function? Bongrand P. Curr Issues Mol Biol 44 505-525 (2022)
  50. Pre-organized landscape of T cell surface. Jung Y. Front Immunol 14 1264721 (2023)
  51. Quantitative Methodologies to Dissect Immune Cell Mechanobiology. Pfannenstill V, Barbotin A, Colin-York H, Fritzsche M. Cells 10 851 (2021)
  52. Recent advances in understanding TCR signaling: a synaptic perspective. Dustin ML. Fac Rev 12 25 (2023)
  53. Biomembrane force probe (BFP): Design, advancements, and recent applications to live-cell mechanobiology. Moldovan L, Song CH, Chen YC, Wang HJ, Ju LA. Exploration (Beijing) 3 20230004 (2023)
  54. Current Trends in Vaccine Development for Hereditary Colorectal Cancer Syndromes. Bowen CM, Sinha KM, Vilar E. Clin Colon Rectal Surg 37 146-156 (2024)
  55. Physical-Chemical Regulation of Membrane Receptors Dynamics in Viral Invasion and Immune Defense. Qin R, An C, Chen W. J Mol Biol 435 167800 (2023)
  56. Biomaterials-mediated ligation of immune cell surface receptors for immunoengineering. Cui H, Zhang L, Shi Y. Immunooncol Technol 21 100695 (2024)
  57. Mathematical models of TCR initial triggering. Shi J, Yin W, Chen W. Front Immunol 15 1411614 (2024)
  58. Mechanical forces amplify TCR mechanotransduction in T cell activation and function. Jeffreys N, Brockman JM, Zhai Y, Ingber DE, Mooney DJ. Appl Phys Rev 11 011304 (2024)
  59. Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy. Shao W, Yao Y, Yang L, Li X, Ge T, Zheng Y, Zhu Q, Ge S, Gu X, Jia R, Song X, Zhuang A. Exp Hematol Oncol 13 37 (2024)
  60. Strategies and rules for tuning TCR-derived therapy. Mo G, Lu X, Wu S, Zhu W. Expert Rev Mol Med 26 e4 (2023)
  61. The recent advancement of TCR-T cell therapies for cancer treatment. Zhao X, Shao S, Hu L. Acta Biochim Biophys Sin (Shanghai) 56 663-674 (2024)

Articles citing this publication (95)



Quick links